Julie L. Gerberding, M.D., M.P.H.
Executive vice president, strategic communications, global public policy and population health and chief patient officer
Julie L. Gerberding is chief patient officer and executive vice president at Merck, where she is responsible for a broad portfolio focused on patient engagement, strategic communications, global public policy, population health and corporate responsibility. She joined the company in 2010 as president of Merck vaccines.
Previously, Julie was director of the U.S. Centers for Disease Control and Prevention (CDC), where she led the agency through 40+ emergency responses to public health crises. She has received more than 50 awards and honors, including the U.S. Department of Health and Human Services (DHHS) distinguished service award for her leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks. She was named to the TIME 100 list of most influential people in 2004 and the Healthcare Businesswomen Association’s Woman of the Year in 2018.
Julie serves on the boards of Biotechnology Innovation Organization (BIO), Cerner Corporation and the MSD Wellcome Trust Hilleman Laboratories, a non-profit that develops new technologies for developing countries. She is a member of the National Academy of Medicine and a fellow of the Infectious Diseases Society of America and the American College of Physicians. She is board certified in internal medicine and infectious diseases. Julie received her undergraduate and M.D. degrees from Case Western Reserve University. She completed her internship and residency in internal medicine and fellowship in clinical pharmacology and infectious diseases at the University of California, San Francisco, where she is currently an adjunct associate professor of medicine. Julie received a Masters of Public Health at the University of California, Berkeley.
Read Julie's latest insights
Lessons from dual pandemics
A conversation with Merck Chief Patient Officer Julie Gerberding, M.D., M.P.H., about her early work caring for people with HIV and AIDS, and the parallels of the AIDS and COVID-19 pandemicsRead more
Next: Lessons from dual pandemics
Antibiotic resistance: the hidden threat lurking behind COVID-19
Written by Julie L. GerberdingRead more
Next: Antibiotic resistance: the hidden threat lurking behind COVID-19
Podcast: How Merck is looking at past epidemics and science to respond to the coronavirus outbreak
Listen as Merck’s Dr. Julie L. Gerberding, chief patient officer, and BIO’s Phyllis Arthur, VP, infectious diseases and diagnostics policy, discuss the outbreak and its public health impact Patrick Ryan, Merck director of communications, recently discussed the coronavirus outbreak with our own Dr. Julie L. Gerberding, executive vice president and chief patient officer, and Phyllis […]Read more
Next: Podcast: How Merck is looking at past epidemics and science to respond to the coronavirus outbreak
Inside Davos 2020: the World Economic Forum
Global health challenges are getting more complex. Our company is working with leaders everywhere to solve them.Read more
Next: Inside Davos 2020: the World Economic Forum